John D. Bucheit

521 total citations
17 papers, 358 citations indexed

About

John D. Bucheit is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John D. Bucheit has authored 17 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John D. Bucheit's work include Diabetes Treatment and Management (6 papers), Lipoproteins and Cardiovascular Health (5 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). John D. Bucheit is often cited by papers focused on Diabetes Treatment and Management (6 papers), Lipoproteins and Cardiovascular Health (5 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). John D. Bucheit collaborates with scholars based in United States, Italy and New Zealand. John D. Bucheit's co-authors include Dave L. Dixon, Evan M. Sisson, Michael S. Kelly, Kevin J. Malloy, Nicole Carter, Roy Brown, Antonio Abbate, Salvatore Carbone, William L. Baker and Leo F. Buckley and has published in prestigious journals such as Journal of the American Heart Association, American Journal of Infection Control and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.

In The Last Decade

John D. Bucheit

14 papers receiving 350 citations

Peers

Countries citing papers authored by John D. Bucheit

Since Specialization

Citations

This map shows the geographic impact of John D. Bucheit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Bucheit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Bucheit more than expected).

Fields of papers citing papers by John D. Bucheit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Bucheit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Bucheit. The network helps show where John D. Bucheit may publish in the future.

Co-authorship network of co-authors of John D. Bucheit

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Bucheit. A scholar is included among the top collaborators of John D. Bucheit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Bucheit. John D. Bucheit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Characterizing pharmacy deserts and designing a model to minimize inequities in pharmacy distribution in Virginia 2025 ·Journal of the American Pharmacists Association ·(unknown), Rachel Wittenauer, (unknown), (unknown), John D. Bucheit, Evan M. Sisson, Jean‐Venable R. Goode, (unknown), Teresa M. Salgado	0
2	Association Between Self‐Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial) 2024 ·Journal of the American Heart Association ·Joshua A. Jacobs, Catherine G. Derington, Alexander R. Zheutlin, Jordan B. King, Jordana B. Cohen, John D. Bucheit, Ian M. Kronish, (unknown), Donald E. Morisky, Tom Greene, Adam P. Bress	3
3	Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies 2023 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Azita H. Talasaz, Anurag Mehta, Michael S. Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon	21
4	Understanding the Role of Finerenone Among Current Treatment Options for Diabetic Kidney Disease 2023 ·(unknown), (unknown), Rachel Flurie, John D. Bucheit	1
5	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health 2022 ·Journal of Cardiovascular Pharmacology ·John D. Bucheit, (unknown), (unknown), (unknown), Evan M. Sisson	9
6	A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study 2021 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), John D. Bucheit	0
7	Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series 2019 ·Pharmacy Practice ·(unknown), John D. Bucheit, Pramit Nadpara, Dave L. Dixon, (unknown), (unknown), Evan M. Sisson	17
8	Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist 2019 ·Diabetes Technology & Therapeutics ·John D. Bucheit, (unknown), Nicole Carter, Kevin J. Malloy, Dave L. Dixon, Evan M. Sisson	106
9	Pharmacist-administered pediatric vaccination services in the United States: major barriers and potential solutions for the outpatient setting 2019 ·Pharmacy Practice ·(unknown), Julie A. Patterson, John D. Bucheit, (unknown), (unknown), (unknown), (unknown)	9
10	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease 2019 ·Current Atherosclerosis Reports ·Dave L. Dixon, (unknown), John D. Bucheit, Evan M. Sisson, (unknown), (unknown), George F. Wohlford, (unknown)	18
11	Evolving Role of Non‐Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future 2017 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Evan M. Sisson, (unknown), John D. Bucheit, Michael S. Kelly, Dave L. Dixon	6
12	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150–499 mg/dL) 2017 ·Journal of clinical lipidology ·Michael S. Kelly, Craig J. Beavers, John D. Bucheit, Evan M. Sisson, Dave L. Dixon	7
13	Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis 2017 ·Journal of the American Heart Association ·William L. Baker, Leo F. Buckley, Michael S. Kelly, John D. Bucheit, (unknown), Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L. Dixon	139
14	Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline 2017 ·Journal of clinical lipidology ·John D. Bucheit, (unknown), Pramit Nadpara, Salim S. Virani, Dave L. Dixon	10
15	Antimicrobial stewardship practices in Virginia 2016 ·American Journal of Infection Control ·(unknown), (unknown), (unknown), John D. Bucheit, Kakotan Sanogo, Michael Stevens	4
16	Hypertension and Diabetes 2016 ·Evan M. Sisson, John D. Bucheit	0
17	Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy 2013 ·American Journal of Health-System Pharmacy ·John D. Bucheit, (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact